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Objective. Our aim was to evaluate the signiﬁcance of homocysteine (Hcy) in Behcet’s disease (BD) and the association of elevated
Hcy levels associated with the indices of inﬂammation in BD. Methods. Untreated 70 patients with BD and 33 healthy individuals
were included into the study. Hcy, tumor necrosis alpha (TNF-α), C-reactive protein (CRP), and erythrocyte sedimentation rate
(ESR) were evaluated with respect to activity and speciﬁc individual clinical manifestations of the disease. Results. Hcy levels were
found signiﬁcantly elevated in active BD when compared to inactive BD and healthy controls. Hcy levels were found to have high
correlationwiththenumberofactiveclinicalmanifestationsincreased.Asigniﬁcantpositivecorrelationwasfoundbetweenserum
Hcy and TNF-α levels, CRP, and ESR. Hcy was found to be the best predictor of TNF-α among other parameters. Conclusion.H c y
may involve in the pathogenesis of BD by inducing inﬂammation.
Copyright © 2008 Selda Pelin Kartal Durmazlar et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
In 1969, McCully ﬁrst proposed homocysteine (Hcy) to be
a cause of cardiovascular disease due to the observation
thatpatientswithhomocystinuria,ametabolicdiseasewhich
results in high Hcy levels, also displayed atherosclerotic
p l a q u e sa ta u t o p s i e s[ 1]. High levels of Hcy were associated
with endothelial damage and oxidative stress [2, 3]. Cur-
rently, there is a classiﬁcation commonly used for the degree
of hyperhomocysteinemia as follows: normal (5–14μmol/L),
mild(15–30μmol/L),moderate(31–100μmol/L),andsevere
(>100μmol/L) [4]. As many epidemiologic studies sup-
ported, mild hyperhomocysteinemia was found risk factor
for both venous and arterial thrombosis [5–8]. Hcy is an
intermediary sulphydryl-containing amino acid formed dur-
ing the conversion of methionine to cysteine. Its sulphydryl
group can cause direct endothelial cytotoxicity, inhibition
of glutathione peroxidase and nitric oxide, interference
with clotting factor, and oxidation of LDL [9]. Addition-
ally, high levels of Hcy cause lipid peroxidation, impaired
vasomotor regulation, prothrombic surface, and, therefore,
atherothrombogenesis [10].
Behcet’s disease (BD), initially described by Behcet in
1937 [11], is a chronic relapsing vasculitis, involving both
arteries and veins of various sizes. Thrombotic complica-
tions have been reported in approximately 10–40% of BD
patients [12]. Endothelial dysfunction due to inﬂammation
is considered to be an important factor of thrombosis in BD.
Homocysteine is reported to enhance endothelial leukocyte
interaction [13]. Some studies have shown that hyperho-
mocysteinemia might be assumed to be an independent
and correctable risk factor for thrombosis in BD [14–19].
Moreover,theassociationbetweenHcylevelsandendothelial
dysfunction has been shown in patients with BD [20].
However, endothelial injury itself cannot clearly account
the hypercoagulable status of BD because other vasculitis
syndromes do not increase the risk of thrombosis [21].
Additionally, existence of several contradictory results with
respect to serum Hcy levels leads the role of homocysteine
in BD unclear [22]. As vitamin B6, vitamin B12, and folic2 Mediators of Inﬂammation
acid can decrease homocysteine levels [23], treatment with
these vitamins can be considered to reduce the risk of venous
and arterial thrombosis. Therefore, it is important to ﬁnd a
clear picture of the role of Hcy, which is thought to induce
proinﬂammatory cytokines [24] during the course of BD.
The present study was conducted to evaluate serum Hcy
as a serological marker for the assessment of the activity of
BDwithrespecttospeciﬁcindividualclinicalmanifestations.
Serum levels of Hcy were compared with the values of C-
reactive protein (CRP), an acute phase reactant, the erythro-
cyte sedimentation rate (ESR), and tumor necrosis alpha
(TNF-α) which is an important proinﬂammatory cytokine.
The results were controlled with the healthy individuals.
In patients with BD, the question of whether hyper-
homocysteinemia depends on the inﬂammation has not
been answered yet. Therefore, our aim was to evaluate
whether elevated Hcy levels, an independent risk factor
for both venous and arterial thrombosis, associated with
proinﬂammatory process mediated by cytokines in patients
with BD.
2. MATERIAL AND METHODS
2.1. Subjects
70 patients (40 males, 30 females; mean age of 33 ± 7.79)
fulﬁlling the international study group criteria [25] for the
diagnosis of BD and 33 healthy control subjects (17 males,
16 females; mean age of 30 ± 6.68) were included in this
study. Patients with BD were selected from patients who
were being followed up by the departments of dermatology
and cardiovascular surgery, Behcet’s Disease Unit or referred
from other departments. Subjects were newly diagnosed or
patients who were not taking any medicine regarding BD
for some reason. The control subjects were age- and sex-
matchedhealthyhospitalstaﬀ.Completebloodcount,serum
glucose, urea, creatinine, total cholesterol, triglyceride, uric
acid, alanine aminotransferase, aspartate aminotransferease,
alkaline phosphatase, vitamin B12, and folic acid levels were
evaluated in all of the subjects before being included into
the study. Patients who had other type of illness such as
autoimmune disease that could aﬀect the cytokine levels
or patients taking any medication aﬀecting the immune
systemorpatientswithfolicacidorvitaminB12deﬁciencies,
diabetes mellitus, hyperlipidemia, chronic hepatitis, renal
failure, severe psoriasis, pernicious anemia, and chronic
alcoholism which might aﬀect Hcy levels were excluded
from the study. Patients taking vitamin supplements in the
previous 6 months were also excluded from the study. The
study was approved by the local ethics institute. Informed
consent was obtained from all subjects. Pathergy test was
performedandthenumberofactivemanifestationsrecorded
for each patient.
2.2. Determinationofdiseaseactivity
Since accepted speciﬁc clinical activity scoring system and
laboratory screening proﬁle for BD has not been performed
sofar,theactivityofpatientswasconsideredtohaveanactive
disease in case of the existence of two or more symptoms
with worsening of clinical symptoms and lack of wellbeing at
the time of the study. Behcet’s disease activity index (BDAI)
was also performed on our patients according to the method
presented by Bhakta et al. [26] and described elaborately
by Lawton et al. [27]. An overall disease activity scores
derived from adding the scores according to the evaluation
of the duration of each clinical features (from 0 to 4) and
patients and clinicians impressions of the disease activity. As
itwasagreedthatinclusionoferythrocytesedimentationrate
(ESR) and C-reactive protein (CRP) measurements would
not add signiﬁcantly to overall measurement of disease
activity [27] and were not included as criteria in BDAI
[26, 27], ESR and CRP were not used in the determination
of the activation of the disease. The patients who had
no symptoms regarding BD in four weeks period or less
than two symptoms with a healing process and an overall
wellbeing status were grouped in inactive BD.
2.3. Vascularexamination
All patients and healthy volunteers were examined carefully
for vascular involvement. Either venous or arterial system
involvement was deﬁned as present when conﬁrmed by
Doppler ultrasonography, radioisotope venography, mag-
netic resonance angiography, conventional angiography, or
computerized tomography.
2.4. Serumhomocysteineanalysis
Serum homocysteine levels in the study groups were deter-
mined by ﬂuorescence polarization immunoassay (FPIA)
technique (Axis Biochemicals, ASA, Oslo, Norway). FPIA
was run on an IMx analyzer (Abbott, Ill, USA). The 95%
conﬁdence interval of plasma Hcy level suggested by the
manufacturer for healthy individuals is 4.45–12.42μmol/L
and serum Hcy level is expected to be up to 10% higher
than ethylenediamine tetraacetate (EDTA) plasma. Five cc
blood samples were drawn using a 25 gauge needle from a
peripheral vein, avoiding haemolysis in the morning hours
after an overnight fasting and 30 minutes of supine rest
and collected into 10mL empty evacuated tubes without
EDTA, heparin, or clot activators. Samples were centrifuged
at 1000 × g for 10 minutes. The serum was separated in
aliquots and immediately frozen and stored at −80◦C within
60 minutes until use.
2.5. Detectionoftumornecrosisalphaby
enzyme-linkedimmunosorbantassay
The TNF-α level was measured with an enzyme-linked
immunosorbant assay (ELISA) kit (Bender Medsystems,
Vienna,Austria,Lot#223/208-D1)withadetectablelevelset
at14pg/mL.Fiveccserumwasseparatedbycentrifugationat
1000 ×g for 10 minutes and stored at −70◦C until use.
2.6. C-reactiveprotein,erythrocyte
sedimentationrateanalyses
CRP was measured by a highly sensitive turbidimetric
method using conventional biochemical automatic analyzer.Selda Pelin Kartal Durmazlar et al. 3
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was determined by the classic Westergren method.
2.7. Statisticalanalysis
Results were analyzed using SPSS for Windows VER 11.5
(SPSS Inc., Chicago, Ill, USA). Each variant was evaluated
by one sample Kolmogorov-Smirnov test for compatibility
with normal distribution. As the data did not ﬁt nor-
mal distribution, the nonparametric Kruskall-Wallis test
for intergroups comparison and Mann-Whitney U test or
Bonferroni corrected Mann-Whitney U tests were used for
between-group comparisons as indicated. The relationship
between variables was evaluated by Spearman correlation
and regression analysis. Levels of signiﬁcance set at 0.05 but
inBonferronicorrectedtestthesigniﬁcancethresholdof0.05
yielded to the value of 0.0167. Data are presented as median
values and their individual ranges (in parenthesis).
3. RESULTS
Detected number of patients suﬀering from individual active
clinical manifestations of the disease in various degrees was
31 with oral ulceration (44.28%), 23 with genital ulceration
(32.85%), 18 with ocular involvement (25.71%), 37 with
vascular involvement (52.85%), 25 with arthritis (35.71%),
and 31 with cutaneous lesions like erythema nodosum
(EN) and papulopustular eruption (PPE) (44.28%). Thirty
ﬁve patients (50%) were found to have positive pathergy
test. According to our evaluation scale, 34 patients were
considered to have active disease with a median of 4
symptoms ranging between 2 and 5 and 36 patients to
have inactive disease with a median of 1 symptom ranging
between 1 and 2. Consistently, active group had a statistically
signiﬁcant high BDAI score with a median of 16 ranging
between 9 and 25 compared to inactive group with a median
o f2r a n g i n gb e t w e e n1a n d5( P = .00) (Table 1). According
to vascular examination, venous involvement (deep venous
thrombosis with or without thromboﬂebitis) was found in
23 patients and either arterial occlusion or aneurysm was
found in 14 patients in active group. 17 patients in inactive
grouphadshortdurationofthromboﬂebitiswithawellbeing
status.
In intergroup comparison of active BD, inactive BD,
and healthy controls according to serum levels of Hcy,
TNF-α, CRP, and ESR signiﬁcant diﬀerence was detected
for each parameter (P = .00 for each parameter) (Table 1).
To determine which group/groups cause the diﬀerence,
between-group comparisons performed. According to this,
Hcy, TNF-α, CRP, and ESR levels were found elevated in
active BD compared to inactive BD and healthy controls.
Hcy, TNF-α, CRP, and ESR levels of inactive BD were
found elevated compared to healthy controls. Hcy and
TNF-α suggested having a strong association of disease
activity (Table 1). Hcy and TNF-α were found to have high
correlation with BDAI scores (r = 0.836, P = .00 and
r = 0.924, P = .00, resp.) and the number of active clinical
manifestations increased (r = 0.694, P = .00 and r =
0.842, P = .00, resp.) while ESR and CRP also showed a
positive correlation with both parameters with relatively less
signiﬁcance (Table 2).
The evaluation of association between speciﬁc individual
clinical manifestations and serum levels revealed increased
Hcy levels in patients with oral ulcer (P = .03), genital ulcer
(P = .005), the presence of positive pathergy test (P =
.007), ocular lesion (P = .00), and vascular lesion of high
signiﬁcance (P = .00) (Table 3). No association was found
between Hcy levels and EN/PPE and arthritis.
The serum levels of TNF-α were found to have strong
association with oral ulcer (P = .00), genital ulcer (P = .00),
the presence of positive pathergy test (P = .00), ocular lesion
(P = .00), and vascular lesion (P = .000) (Table 4). No
association was found between TNF-α levels and EN/PPE
and arthritis.
The association of CRP with genital ulcer (P = .001),
ocular lesion (P = .001), vascular lesion (P = .001), EN/PPE
(P = .043), and the presence of positive pathergy test (P =
.016) was found. No association was found between CRP
levels and ocular lesion and arthritis (Table 5). ESR showed
no signiﬁcant association with any of the speciﬁc individual
clinical manifestations (Table 6).
A signiﬁcant positive correlation was found between
serum Hcy and TNF-α levels (r = 0.89, P = .00), CRP
(r = 0.645, P = .00) and ESR (r = 0.561, P = .00) (Table 2).
Among parameters, Hcy was found to be the best predictor
of TNF-α which was used as a dependent variable (Beta =
6.45, R2 = 0.88, P = .00) (Table 7).
Serum levels of Hcy in active BD patients with vas-
cular involvement were found signiﬁcantly increased when
compared in patients with active BD without vascular
involvement. In addition, serum levels of Hcy in inactive BD
with vascular involvement were found signiﬁcantly increased
compared to inactive BD (Table 8).
Serum levels of active BD patients with vascular involve-
ment, oral ulcer, arthritis/arthralgia, EN/PPE and the pres-
ence of positive pathergy test were found signiﬁcantly
increased compared to inactive BD patients with the same
clinical symptoms (Table 9).
4. DISCUSSION
The main pathology in BD is an inﬂammatory process
of small arteries and veins and thrombosis as a result of
vasculitis of the vaso vasorum [24]. Hyperhomocysteinemia
has been shown to be a risk factor for thrombosis in BD in
some recent studies [14–19]. In our study, serum levels of
Hcy were found to have a positive correlation with BDAI
scores and total number of active clinical manifestations.
We also found signiﬁcantly elevated levels of serum total
Hcy in active BD when compared with inactive and control
groups. Our results supported that total serum Hcy was a
reliable marker for the activity of disease [17]. Aksu et al.
[14] divided their patients with BD into two groups on the
basis of thrombosis and they found hyperhomocysteinemia
inpatientswithahistoryofthrombosis.However,Leibaetal.
[22] could not ﬁnd diﬀerent serum total Hcy levels between
patients with and without a history of thrombosis. The
main limitations of this study were its retrospective nature4 Mediators of Inﬂammation
Table 1: Comparision of serum homocysteine, TNF-α, CRP, and ESR values and BDAI scores between groups.
Homocysteine (μmol/L) TNF-α (pg/mL) ESR (mm/h) CRP (mg/L) BDAI scores
Median (range)
Group I (active BD) (n = 34) 20.95 (13.7–39.25) 93.5 (30–228) 24 (2–95) 20.5 (3–400) 16 (9–25)
Group II (inactive BD) (n = 36) 13 (6.43–18) 19 (15–30) 27 (8–49) 6.65 (3–34) 2 (1–5)
Group III (healthy control) (n = 33) 8 (5–8) 0 (0–18) 6 (2–18) 3.1 (3–10)
Signiﬁcance for groups
I-II-III aP = .00
∗ aP = .00
∗ aP = .00
∗ aP = .00
∗
cP = .00
∗ I-II bP = .00
∗ bP = .00
∗ bP = .001
∗ bP = .00
∗
I-III bP = .00
∗ bP = .00
∗ bP = .00
∗ bP = .00
∗
II-III bP = .00
∗ bP = .00
∗ bP = .008
∗ bP = .00
∗
aP∗ Signiﬁcantly diﬀerent by Kruskal-Wallis test (P<. 05).
bP∗ Signiﬁcantly diﬀerent by Bonferroni corrected Mann-Withney U test (P<. 0167).
cP∗ Signiﬁcantly diﬀerent by Mann-Withney U test (P<. 05).
Data are presented as median values and their individual ranges within parentheses.
Table 2: The relationship between variables.
Hcy ESR CRP TNF Total† BDAI
Spearman correlation coeﬃcient and P-values
Hcy r = 0.561 r = 0.645 r = 0.889 r = 0.694 r = 0.836
P = .00 P = .00 P = .00 P = .00 P = .00
ESR r = 0.561 r = 0.421 r = 0.538 r = 0.304 r = 0.408
P = .00 P = .00 P = .00 P = .011 P = .00
CRP r = 0.645 r = 0.421 r = 0.670 r = 0.549 r = 0.583
P = .00 P = .00 P = .00 P = .00 P = .00
TNF r = 0.889 r = 0.538 r = 0.670 r = 0.842 r = 0.924
P = .00 P = .00 P = .00 P = .00 P = .00
Total† r = 0.694 r = 0.304 r = 0.549 r = 0.842 r = 0.842
P = .00 P = .011 P = .00 P = .00 P = .00
BDAI r = 0.836 r = 0.408 r = 0.583 r = 0.924 r = 0.842
P = .00 P = .00 P = .00 P = .00 P = .00
Total† number of active clinical manifestations for each patient.
and the long lag period between the thrombotic events and
the time of analyses performed. Aksu et al. [14]e v a l u a t e d
their patients with respect to current clinical activity and
10 patients were accepted as clinically active, though they
could not ﬁnd association between serum Hcy levels and
disease activity. The small sample size was a limitation of this
study.
The main factor responsible for the increased frequency
of thrombosis in BD is thought to be endothelial dysfunction
caused by vascular inﬂammation [14, 15]. The association
between Hcy levels and endothelial dysfunction and its
correlation to the degree of endothelial damage has been
shown in patients with BD [20]. Hcy generates superoxide
and hydrogen peroxide, both of which have been linked to
endothelialdamage[15].Hcy-inducedvascularproblemsare
thought to be multifactorial, including direct Hcy damage to
the endothelium, enhanced lipid peroxidation and increased
platelet aggregation by the eﬀects on the coagulation system
[15, 17].
In our study, the evaluation of association between
speciﬁc individual clinical manifestations and serum levels
revealed increased Hcy levels in patients with oral ulcer,
genital ulcer, the presence of positive pathergy test and
particularly with ocular and vascular lesions of high signif-
icance. No association was found between Hcy levels and
EN/PPE and arthritis. Er et al. [15] showed the association
of Hcy levels with disease activity and ocular BD. Other
speciﬁc individual clinical manifestations were not assessed
in this study. Ates ¸ et al. [16] showed the association of Hcy
levels with vascular involvement in BD. However, they could
not ﬁnd statistically signiﬁcant diﬀerence between active
and inactive diseases and association with mucocutaneous
involvement in BD. On the other hand, Korkmaz et al.
[28] reported no statistically signiﬁcant association between
vascular involvement and homocysteine levels, though 50%
of patients with vascular involvement had hyperhomocys-
teinemia. Although the mechanism is unknown, all these
ﬁndings indicate that Hcy associates with BD. However,
the causes of these diﬀerent study outcomes are not clear.
The diﬀerent sample sizes, diﬀerent disease durations or
study patients under treatment that might aﬀect outcomes
might have contributed. In addition, the question whether
hyperhomocysteinemia depends on the inﬂammation or not
remains to be unanswered.Selda Pelin Kartal Durmazlar et al. 5
Table 3: The signiﬁcance of the association of Hcy with versus without individual clinical manifestations and pathergy reaction.
Hcy levels (μmol/L) in patients with Hcy levels (μmol/L) in patients without
Manifestations No. of Patients Median (Range) Median (Range) P-values
Oral ulcer 31 18.03 (8–39.3) 14.28 (6.4–29) P = .003
∗
Genital ulcer 23 18.1 (11.9–38.1) 14.28 (6.4–39.3) P = .005
∗
Ocular lesion 18 21.59 (14–39.3) 14.15 (6.4–38) P = .00
∗
Vascular lesion 37 19 (11.9–39.3) 13.75 (6.4–26) P = .00
∗
Arthritis/arthralgia 25 16 (6.4–39.3) 15 (8–38.1) P = .99
EN/PPE 31 16 (8.1–38.1) 14.88 (6.4–39.3) P = .306
(+) pathergy 35 17.2 (7.9–38.1) 14 (6.4–39.3) P = .007
∗
P∗ <. 05 by Mann-Whitney U test (statistically signiﬁcant with versus without clinical manifestations).
Data are presented as median values and their individual ranges within parentheses.
Table 4: The signiﬁcance of the association of TNF-α with versus without individual clinical manifestations and pathergy reaction.
TNF-α levels (pg/mL) in patients with TNF-α levels (pg/mL) in patients without
Manifestations No. of patients Median (Range) Median (Range) P-values
Oral ulcer 31 70 (15–228) 20 (15–150) P = .00
∗
Genital ulcer 23 54 (17–228) 21 (15–228) P = .00
∗
Ocular lesion 18 99 (30–228) 21 (15–180) P = .00
∗
Vascular lesion 37 84 (15–228) 21 (15–145) P = .00
∗
Arthritis/arthralgia 25 38 (15–228) 28 (15–228) P = .49
EN/PPE 31 45 (15–228) 22 (15–228) P = .086
(+) pathergy 35 45 (15–228) 21 (15–228) P = .00
∗
P∗ <. 05 by Mann-Whitney U test (statistically signiﬁcant with versus without clinical manifestations).
Data are presented as median values and their individual ranges within parentheses.
Table 5: The signiﬁcance of the association of CRP with versus without individual clinical manifestations and pathergy reaction.
CRP levels (mg/L) in patients with CRP levels (mg/L) in patients without
Manifestations No. of patients Median (Range) Median (Range) P-values
Oral ulcer 31 12.4 (3–400) 8.7 (3–43) P = .159
Genital ulcer 23 18 (3–100) 8.4 (3–400) P = .001
∗
Ocular lesion 18 19.25 (3–400) 8.5 (3–68) P = .001
∗
Vascular lesion 37 20.5 (3–400) 8.4 (3–51) P = .001
∗
Arthritis/arthralgia 25 8.4 (3–400) 12.9 (3–400) P = .201
EN/PPE 31 12.9 (3–400) 8.9 (3–400) P = .043
∗
(+) pathergy 35 14.8 (3–400) 8.7 (3–400) P = .016
∗
P∗ <. 05 by Mann-Whitney U test (statistically signiﬁcant with versus without clinical manifestations).
Data are presented as median values and their individual ranges within parentheses.
Table 6: The signiﬁcance of the association of ESR with versus without individual clinical manifestations and pathergy reaction.
ESR levels (mm/h) in patients with ESR levels (mm/h) in patients without
Manifestations No. of patients Median (Range) Median (Range) P-values
Oral ulcer 31 21 (2–95) 12 (2–70) P = .113
Genital ulcer 23 22 (2–95) 14 (2–60) P = .121
Ocular lesion 18 22 (2–86) 14 (2–95) P = .291
Vascular lesion 37 20 (2–70) 14 (2–95) P = .642
Arthritis/arthralgia 25 22 (3–60) 14 (2–95) P = .317
EN/PPE 31 24 (2–95) 12 (2–70) P = .070
(+) pathergy 35 22 (2–95) 14 (3–49) P = .173
P∗ <. 05 by Mann-Whitney U test (statistically signiﬁcant with versus without clinical manifestations).
Data are presented as median values and their individual ranges within parentheses.6 Mediators of Inﬂammation
Table 7: Predictors of plasma TNF-α level: regression analysis.
Predictor of TNF-αR 2 Beta P-value
Hcy 0.88 6.45 P = .00
CRP 0.39 0.559 P = .00
ESR 0.146 1.15 P = .00
Dependent variable: TNF-α.
Although the etiopathogenesis of BD has not yet been
clariﬁed, diﬀerent immunological abnormalities have been
reported and increased spontaneous secretion of TNF-α,
Interleukin-6 (IL-6), and Interleukin-8 (IL-8) in monocyte
cultures obtained from BD patients [29]. Necrotizing, neu-
trophilic (leukocytoclastic) obliterative perivasculitis, and
venous thrombosis with lymphocytic and monocytic cellular
inﬁltration of the veins, capillaries, and the arteries of all
sizes and endothelial dysfunction are the hallmarks of BD
[30]. Histopathological studies revealed cellular inﬁltration
consisting of lymphocytes, plasmocytes, monocytes, and
peripheral polymorphonuclear leukocytes (PMNs) in vary-
ing degrees, depending on the stage of lesion in BD [30, 31].
Since cytokines are involved in the regulation of functions
of lymphocytes and phagocytes, they are playing important
role in the pathogenesis of the disease [30, 31]. Although
any organ system may be aﬀected, there is high prevalence
of venous or arterial thrombosis in BD and most clinical
features are associated with systemic vasculitis. It has been
suggested that vasculo-Behcet disease should be classiﬁed as
a neutrophilic vasculitis targeting the vaso vasorum [32].
Aneurysm formation may be related to degeneration of
arterial wall caused by inﬂammation of the vaso vasorum.
As Hcy has profound eﬀects concerning vascular lesions
and thrombosis, vascular and ocular involvements in BD
deserve special attention. Indeed, we found signiﬁcantly
elevated levels of Hcy with respect to the presence of vascular
involvement in the intragroup comparisons of separately
active and inactive BD patients. However, in our study Hcy
was found to be able to evaluate the ﬂuctuating activity of
disease in an objective fashion and the number of additional
organ systems aﬀected. This ﬁnding may imply that Hcy
cannot simply be assumed to be an independent risk factor
for only vascular and ocular vaso-occlusive diseases in BD
[14–19]. That is because most clinical features are thought
to be associated with systemic vasculitis and dermal blood
vessels embolized by thrombus are observed even at the
sites of needle-prick reaction [30]. Furthermore, endothelial
injury is a characteristic ﬁnding in BD and can be observed
even in patients without any clinical vascular involvement
[24, 33, 34]. These data provides insight as to why Hcy is
able to detect overall disease activity with respect to diﬀerent
system involvements and why ascribed signiﬁcance of Hcy is
not limited only to the individual clinical manifestations of
vascularorvaso-occlusiveocularinvolvements?Consistently,
we found the association of Hcy not only with vascular and
ocularvaso-occlusivediseasebutalsowithgenitalulceration,
positive pathergy test, and oral ulcers in BD patients, though
withlesssigniﬁcance.Therefore,ourresultsnotonlysupport
thesuggestionthatHcyisariskfactorforvascularandocular
vaso-occlusive diseases in BD [15, 16] but also identify Hcy
as a risk factor for the development of most clinical features
that are known to be associated with vasculitis.
We found a signiﬁcant positive correlation between
serum Hcy, TNF-α and CRP levels, and ESR with relatively
less signiﬁcance. Hcy was found to be the best predictor
of TNF-α among other parameters. In other words, Hcy
was found to explain 88% of TNF-α change while CRP and
ESR were found to explain 39% and 14% of TNF-α change,
respectively. The signiﬁcance of Hcy in BD represents either
vascular endothelium damaged by Hcy or immune system
stimulation by Hcy, our study may demonstrate the link
between Hcy and inﬂammation pathways in BD. That is
because TNF-α, CRP, and ESR are indices of inﬂammation.
Although there are conﬂicting results in the literature with
respect to the reliability of ESR and CRP as markers
to detect the activity of BD and they are currently not
involved as criteria in BDAI scores [27], CRP deserves
special attention because it has a strong predictive power of
vascular events [35]. We found both of them were elevated
in the active stage of the disease. However, unlike CRP, ESR
showed no signiﬁcant association with any of the speciﬁc
individual clinical manifestations. Relatively large sample
size of our patients with vascular involvement might be a
factoraﬀectingourstudyoutcomeinfavorofthesigniﬁcance
of CRP in BD.
Chemotactic and phagocytic activities of neutrophils in
patients with BD have been reported to be high [31]a n d
TNF-α is a major factor modulating inﬂammatory responses
which is known to be increased in inﬂammatory diseases.
Recent studies showed increased TNF-α level in BD patients,
especially in the exacerbation period [24, 30]. Synthesis of
CRP in the liver is induced by several proinﬂammatory
cytokines including TNF-α. This marks CRP as a precise
objective index of inﬂammatory activity and surrogate
of underlying cytokine stimulus and a sensitive marker
of underlying systemic inﬂammation [35]. It has been
demonstrated that coagulation indices including ﬁbrinogen,
von Willebrand factor, and plasminogen activator activity
are increased in BD and Hcy is thought to promote the
clotting cascade via several actions including inactivation
of protein C, activation of coagulation factor V, increased
vascular smooth muscle cell proliferation, and inhibition
of thrombomodulin [15]. CRP is thought to have eﬀects
into the mechanism linking inﬂammation and coagulation
[35]. Hcy is thought to induce proinﬂammatory cytokines
[24, 36–38]. In vasculitis such as BD, endothelial-leukocyte
interaction is an important part of the inﬂammation [21]
and Hcy has been reported to increase endothelial-leukocyte
interaction [13]. Hcy has been shown in vivo and in vitro
to promote inﬂammatory process such as the adhesion of
neutrophils to endothelial cells as well as the release of the
inﬂammatory cytokine IL-8 and monocyte chemoattractant
protein-1 (MPC-1) [39]. Hcy was shown to enhance the
cytokine-stimulated expression of endothelial cell adhesion
molecules and monocyte and T-cell adhesion to endothelial
cells [39]. Adhesion molecules are characterized not only by
their ability to cause directed migration of leukocytes into
inﬂamed tissue, but they may also have biological eﬀects onSelda Pelin Kartal Durmazlar et al. 7
Table 8: Comparison of Hcy intragroups of active and inactive patients according to presence of vascular involvement.
Hcy levels (μmol/L)
Median Range P- values
Active BD (n = 34) With vascular involvement (n = 20) 26 19–39.25 .00
∗
Without vascular involvement (n = 14) 15.98 13.7–26
Inactive BD (n = 36) With vascular involvement (n = 17) 14.28 11.94–18 .00
∗
Without vascular involvement (n = 19) 10.75 6.43–16
P∗ <. 05 by Mann-Whitney U test. Data are presented as median values and their individual ranges.
Table 9: Comparison of Hcy between groups of active and inactive patients according to the presence of individual clinical manifestations
and positive pathergy.
No. of patients Hcy levels (μmol/L) P-values
Active Inactive Active Inactive
Vascular involvement 20 17 26 (19–39.25) 14.28 (11.94–18) .00
∗
Oral ulcer 26 5 20.85 (13.7–39.25) 11.94 (8–14) .00
∗
Arthritis/arthralgia 14 11 19 (13.7–19) 10.83 (6.43–17) .00
∗
EN/PPE 21 10 19 (13.7–38.1) 12.36 (8.1–16) .00
∗
Positive pathergy 24 11 20.85 (13.7–38.1) 14.28 (7.91–17.21) .00
∗
P∗ <. 05 by Mann-Whitney U test. Data are presented as median values and their individual ranges.
other cell types, such as endothelial cells, ﬁbroblasts, and
smooth muscle cells [40]. Hcy was shown to promote TNF-
α mediated induction of vascular cell adhesion molecule-1
(VCAM-1) in endothelial cells [41]. With respect to innate
inﬂammatory markers such as TNF-α and CRP, serum Hcy
has been shown to contribute to innate immune response
and to be a determinant of TNF-α in hypertensive patients
[36]. In addition, Hcy has been shown to enhance inﬂam-
mation markers in murine models [42]. The correlation of
Hcy levels with nitric oxide has been shown in patients with
BD [15]. Hcy is known to increase nitric oxide production
in vascular smooth muscle cells and nitric oxide is known to
be released as a response to systemic immunoinﬂammatory
diseases [15]. A study demonstrated that targeting the
TNF pathway signiﬁcantly decreased Hcy and CRP levels
in patients with psoriatic arthritis and in this study, CRP
showed a positive correlation with Hcy at baseline [43]. CRP
has been shown to correlate with Hcy in BD [19]. Hcy has
been suggested to be related to the markers of inﬂammation
and its elevated levels as a result of immunosuppressive
treatment [19]. Indeed, immunosuppressive treatments may
aﬀect serum levels of Hcy and TNF-α [44]. This is the reason
why we studied with the patients who were not taking any
medication regarding BD. This deﬁnite selection decreased
the number of our study population as a study limitation. In
our study, serum levels of active BD patients with vascular
involvement, oral ulcer, arthritis/arthralgia, EN/PPE and the
presence of positive pathergy test were found signiﬁcantly
increased compared to inactive BD patients with the same
clinical symptoms. Therefore, serum levels of Hcy were
found to explain the wide clinical spectrum of the activity
of the speciﬁc individual symptoms.
In summary, Hcy and CRP have eﬀects into the
mechanism linking inﬂammation and coagulation and Hcy
is thought to induce proinﬂammatory cytokines includ-
ing TNF-α, which is known to increase chemotactic and
phagocytic activities of neutrophils, endothelial-leukocyte
interaction, and CRP levels. We found a high correlation
between serum levels of Hcy and TNF-α and Hcy was
found to explain the wide clinical spectrum of the activity
of the disease and speciﬁc individual symptoms. Taking all
these ﬁndings into account, a theory might be put forward
which is open to further in vivo and in vitro studies; Hcy-
induced inﬂammation may be responsible for tissue damage
as well as endothelial dysfunction in BD and enhanced Hcy
may account for the diﬀerences observed between clini-
cally distinct subgroups.Lowering Hcyby selected vitamin
supplements or TNF blockade may be the future direction
of prevention from developing the risk of thrombosis and
vasculitis of diﬀerent organ systems and thereby activation
of BD disease.
5. CONCLUSION
Our data identiﬁed Hcy as a risk factor for the development
of not only vascular and ocular involvement but also most
clinical features that are known to be associated with vasculi-
tisinBD.Inaddition,serumHcyshowedastrongassociation
of disease activity and correlated with BDAI scores and
the number of active clinical manifestations increased.
Therefore, Hcy might be assumed as a reliable marker for the
activity of disease. Hcy was found to be the best predictor of
TNF-α and positively correlated with inﬂammatory markers.
Our ﬁndings suggest that Hcy might contribute to the
pathogenesis of BD by inducing inﬂammation. Further
investigation in clinical and experimental studies is required
toconclusivelydemonstratetheassociationbetweenHcyand
inﬂammatory pathways.8 Mediators of Inﬂammation
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